Open AccessLong-Term Efficacy and Safety of Anlotinib as a Monotherapy and Combined Therapy for Advanced Sarcoma
Author(s) -
Weitao Yao,
Xuehui Du,
Jiaqiang Wang,
Xin Wang,
Peng Zhang,
Xiaohui Niu
Publication year - 2022
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s365506
Subject(s) - medicine , sarcoma , response evaluation criteria in solid tumors , combination therapy , chemotherapy , odds ratio , progressive disease , oncology , synovial sarcoma , surgery , soft tissue sarcoma , clinical trial , pathology
To analyze the effectiveness of the long-term (> 12 months) administration of anlotinib as a monotherapy or combined therapy in patients with advanced sarcomas.